on August 2, 2007
Published online before print August 2, 2007, doi: 10.1161/STROKEAHA.107.489112
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 23, 2007
From the Department of Neurology (R.S., K.P., S.R., C.E., F.F.) and, the Division of Neuroradiology (R.S., C.E.), Department of Radiology, Medical University of Graz, Austria. * To whom correspondence should be addressed. E-mail: reinhold.schmidt{at}meduni-graz.at.
Background and Purpose—Leukoaraiosis is used interchangeably with the term white matter lesions on MRI and seen to some degree in more than half of the routine scans in older persons. Clinicians often struggle to explain the implications of these findings to their patients. Recent data on the progression rate of ischemic white matter damage and its cognitive consequences may help in patient counseling and have implications on treatment trials in vascular cognitive impairment. Summary of Review—Leukoaraiosis progresses over time. Its extent at baseline is an important predictor for the subsequent rate of lesion progression. Subjects with punctate abnormalities on MRI have a low tendency for progression, individuals with early confluent and confluent changes tend to progress rapidly. Differences in measurement methods and cohort composition make it difficult to compare progression rates reported by different studies. Nevertheless, in community-dwelling cohorts, white matter lesions volume increased by as much as one quarter per year in subjects with confluent abnormalities at baseline. Progression of leukoaraiosis relates to cognitive decline, but this association is complex and modulated by other morphological factors like brain atrophy. Conclusions—Evidence for rapid progression of widespread leukoaraiosis and the associated cognitive decline in domains particularly affected by cerebral small vessel disease has set the stage for exploratory clinical trials in vascular cognitive impairment using white matter lesions progression as a surrogate marker.
Revised on May 22, 2007
Accepted on June 7, 2007
Progression of Leukoaraiosis and Cognition
Reinhold Schmidt MD*;
Key words: cognition • leukoaraiosis • MRI
This article has been cited by other articles:
 |
|
 |
|
  B. Pieters, J. Staals, I. Knottnerus, R. Rouhl, P. Menheere, A. Kessels, and J. Lodder Periventricular White Matter Lucencies Relate to Low Vitamin B12 Levels in Patients With Small Vessel Stroke Stroke, May 1, 2009; 40(5): 1623 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Saba, R. Sanfilippo, L. Pascalis, R. Montisci, and G. Mallarini Carotid Artery Abnormalities and Leukoaraiosis in Elderly Patients: Evaluation with MDCT Am. J. Roentgenol., February 1, 2009; 192(2): W63 - W70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. van Dijk, N. D. Prins, H. A. Vrooman, A. Hofman, P. J. Koudstaal, and M. M.B. Breteler Progression of Cerebral Small Vessel Disease in Relation to Risk Factors and Cognitive Consequences: Rotterdam Scan Study Stroke, October 1, 2008; 39(10): 2712 - 2719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Knecht, C. Oelschlager, T. Duning, H. Lohmann, J. Albers, C. Stehling, W. Heindel, G. Breithardt, K. Berger, E. B. Ringelstein, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy Eur. Heart J., September 1, 2008; 29(17): 2125 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pantoni Leukoaraiosis: From an Ancient Term to an Actual Marker of Poor Prognosis Stroke, May 1, 2008; 39(5): 1401 - 1403. [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick and J. V. Bowler Advances in Vascular Cognitive Impairment 2007 Stroke, February 1, 2008; 39(2): 279 - 282. [Full Text] [PDF]
|
|